Preclinical Formulation

The first (pre-clinical) formulation effort for a new API will usually be to prepare a solution formulation for IV administration as part of a toxicity test. Poorly soluble compounds present significant challenges in this respect.

There are a number of pre-clinical formulation strategies available and Pharmaterials has helped many companies in this phase of work. We will assess:

• The effect of pH
• Co-solvents
• Surfactants
• Cyclodextrin inclusion complex formation
• Lipid based formulations

We are able to screen these different options rapidly using our  MacroSOLV® formulation technologies to facilitate the pre-clinical development of poorly soluble drugs.